Rapamycin combined with osimertinib alleviated non-small cell lung cancer by regulating the PARP, Akt/mTOR, and MAPK/ERK signaling pathways - Ma, Qingrong; Chen, Kai; Xiao, Haiping (Frontiers in Molecular Biosciences, 2025)